Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactic acid bacteria probiotic
- Development stage
- Unknown
- Lead developer
- TNO
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
The lactic acid bacteria probiotic is a high-dose investigational live biotherapeutic product developed by TNO (Netherlands Organisation for Applied Scientific Research). It consists of a specific blend of live lactic acid bacteria (LAB) strains as the active ingredient. The product is designed to modulate the gut mucosal immune system and intestinal microbiota to prevent or mitigate gastrointestinal disturbances. It has been evaluated in randomized, placebo-controlled human challenge trials involving healthy volunteers infected with attenuated enterotoxigenic *Escherichia coli* (ETEC) to assess its efficacy in reducing mucosal inflammation and traveler's diarrhea. The mechanism of action involves the stabilization of gut bacterial populations, modulation of innate immunity, and protection against pathogen-induced dysbiosis.
- Other names
- high-dose probiotic lactic acid bacteriaLAB probiotic
02
Targets
TLR5TLR2 (Toll-like Receptor 2)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on lactic acid bacteria probiotic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactic acid bacteria probiotic.